Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.79 |
| ▸ | NAAA | Q02083 | 1/20 | 0.73 |
| ▸ | FAAH | O00519 | 4/20 | 0.68 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890024 | 0.98 | CASP2 (0.83) | CASP2NAAAFAAHDNM1EPHX2 | |
| SCHEMBL890027 | 0.98 | CASP2 (0.83) | CASP2NAAAFAAHDNM1EPHX2 | |
| SCHEMBL890026 | 0.98 | CASP2 (0.83) | CASP2NAAAFAAHDNM1EPHX2 | |
| SCHEMBL890029 | 0.98 | CASP2 (0.83) | CASP2NAAAFAAHDNM1EPHX2 | |
| SCHEMBL7695217 | 0.98 | CASP2 (0.83) | CASP2NAAAFAAHDNM1EPHX2 | |
| SCHEMBL6251200 | 0.98 | CASP2 (0.83) | CASP2NAAAFAAHDNM1EPHX2 | |
| SCHEMBL13335016 | 0.98 | CASP2 (0.83) | CASP2NAAAFAAHDNM1EPHX2 | |
| SCHEMBL890028 | 0.98 | CASP2 (0.83) | CASP2NAAAFAAHDNM1EPHX2 | |
| SCHEMBL21233150 | 0.98 | CASP2 (0.83) | CASP2NAAAFAAHDNM1EPHX2 | |
| SCHEMBL10149475 | 0.98 | CASP2 (0.83) | CASP2NAAAFAAHDNM1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0272228-B1 | NEW DERIVATIVES OF 5-PENTYLAMINO-5-OXOPENTANOIC AND 4-PENTYLAMINO-4-OXO-BUTANOIC ACIDS WITH ANTAGONISTIC ACTIVITY TOWARDS CHOLECYSTOKININ AND A METHOD FOR THEIR PREPARATION | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 1992-02-05 | — | — | EP | claimed |
| US-12398444-B2 | Diglycolamide derivatives for separation and recovery of rare earth elements from aqueous solutions | UT-BATTELLE, LLC (US) | 2025-08-26 | — | — | US | disclosed |
| US-11945171-B2 | 3D printing build materials and support materials comprising a phosphor | 3D SYSTEMS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230366059-A1 | METHOD FOR SEPARATION OF ADJACENT LANTHANIDE ELEMENTS | UT-BATTELLE, LLC | 2023-11-16 | — | — | US | disclosed |
| EP-4175941-A2 | METHODS FOR SEPARATION AND RECOVERY OF RARE EARTH ELEMENTS FROM AQUEOUS SOLUTIONS USING DIGLYCOLAMIDE DERIVATIVES | UT-Battelle, LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| EP-4175940-A1 | DIGLYCOLAMIDE DERIVATIVES FOR SEPARATION AND RECOVERY OF RARE EARTH ELEMENTS FROM AQUEOUS SOLUTIONS | UT-Battelle, LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20220410494-A1 | 3D PRINTING BUILD MATERIALS AND SUPPORT MATERIALS COMPRISING A PHOSPHOR | 3D SYSTEMS, INC. | 2022-12-29 | — | — | US | disclosed |
| US-11247386-B2 | Method of verifying integrity of a post-process removal of support material | 3D SYSTEMS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| WO-2022010759-A2 | METHODS FOR SEPARATION AND RECOVERY OF RARE EARTH ELEMENTS FROM AQUEOUS SOLUTIONS USING DIGLYCOLAMIDE DERIVATIVES | UT-BATTELLE, LLC (US) | 2022-01-13 | — | — | WO | disclosed |
| WO-2022010758-A1 | DIGLYCOLAMIDE DERIVATIVES FOR SEPARATION AND RECOVERY OF RARE EARTH ELEMENTS FROM AQUEOUS SOLUTIONS | UT-BATTELLE, LLC (US) | 2022-01-13 | — | — | WO | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| CN-1036394-C | Process for preparing quinolone derivatives | OTSUKA PHARMA CO LTD (JP) | 1997-11-12 | — | — | CN | disclosed |
| EP-0662964-B1 | HETEROCYCLIC AMINES HAVING CALMODULIN ANTAGONIST PROPERTIES | BRITISH TECH GROUP (GB) | 1997-06-11 | — | — | EP | disclosed |
| US-5614519-A | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists | KARL THOMAE GMBH (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5602127-A | ADMINISTERING TO TREAT HYPERTENSION | KARL THOMAE GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| CN-1091288-A | The oxytocin antagonist | OTSUKA PHARMA CO LTD (JP) | 1994-08-31 | — | — | CN | disclosed |
| CN-1046529-A | Carbostyril derivative | OTSUKA PHARMA CO LTD (JP) | 1990-10-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398444-B2 | Diglycolamide derivatives for separation and recovery of rare earth elements from aqueous solutions | GNE, GALE, ARGLU1 | CASP2 4128/4885NAAA 588/4885FAAH 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.